Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines

References

• Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, . EAU guidelines on prostate cancer. Eur Urol 2008;53:68–80.
   PubMed Web of Science ®Google Scholar
• Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, . Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88:2961–78.
   PubMedGoogle Scholar
• Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000;82:1459–68.
   PubMed Web of Science ®Google Scholar
• Mackie PS, Fisher JL, Zhou H, Choong PF. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer 2001;84: 951–8.
   PubMed Web of Science ®Google Scholar
• Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998;12:220–9.
   PubMed Web of Science ®Google Scholar
• Riebeling C, Forsea AM, Raisova M, Orfanos CE, Geilen CC. The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro. Br J Cancer 2002;87: 366–71.
   PubMed Web of Science ®Google Scholar
• Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001;61:2602–8.
   PubMed Web of Science ®Google Scholar
• Tassone P, Tagliaferri P, Viscomi C, Palmieri C, Caraglia M, D'Alessandro A, . Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 2003;88:1971–8.
   PubMed Web of Science ®Google Scholar
• Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000;15:2211–21.
   PubMed Web of Science ®Google Scholar
• Dumon JC, Journe F, Kheddoumi N, Lagneaux L, Body JJ. Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells. Eur Urol 2004;45:521–8.
   PubMed Web of Science ®Google Scholar
• Jagdev SP, Coleman RE, Shipman CM, Rostami H, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel. Br J Cancer 2001;20:1126–34.
   Google Scholar
• Magnetto S, Boissier S, Delmas PD, Clezardin P. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 1999;83:263–9.
   PubMed Web of Science ®Google Scholar
• Karabulut B, Erten C, Gul MK, Cengiz E, Karaca B, Kucukzeybek Y, . Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. Cell Biol Int 2009;33:239–46.
   PubMed Web of Science ®Google Scholar
• Goffinet M, Thoulouzan M, Pradines A, Lajoie-Mazenc I, Weinbaum C, Faye JC, . Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer 2006;6:60.
   PubMed Web of Science ®Google Scholar
• Senaratne SG, Mansi JL, Colston KW. The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. Br J Cancer 2002;86:1479–86.
   PubMed Web of Science ®Google Scholar
• Nogawa M, Yuasa T, Kimura S, Kuroda J, Segawa H, Sato K, . Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells. Oncol Res 2005; 15:1–9.
   PubMed Web of Science ®Google Scholar
• Marra M, Santini D, Meo G, Vincenzi B, Zappavigna S, Baldi A, . Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells. Int J Cancer 2009;125:2004–13.
   PubMed Web of Science ®Google Scholar
• Benford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999;56:131–40.
   PubMed Web of Science ®Google Scholar
• Morgan C,Wagstaff J. Is there a role for ibandronate in the treatment of prostate cancer patients with bony metastases? Acta Oncol 2009;48:882–9.
   PubMedGoogle Scholar
• Ohlmann CH, Jung C, Jaques G. Is growth inhibition and induction of apoptosis in lung cancer cell lines by fenretinide [N-(4-hydroxyphenyl)retinamide] sufficient for cancer therapy? Int J Cancer 2002;100:520–6.
   PubMed Web of Science ®Google Scholar
• Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design. J Natl Cancer Inst 1994;86:1517–24.
   PubMed Web of Science ®Google Scholar
• Caraglia M, Marra M, Naviglio S, Botti G, Addeo R, Abbruzzese A. Zoledronic acid: An unending tale for an antiresorptive agent. Expert Opin Pharmacother 2010;11:141–54.
   PubMed Web of Science ®Google Scholar
• Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, . Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000; 60:2949–54.
   PubMed Web of Science ®Google Scholar
• Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, . Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997;57:3890–4.
   PubMed Web of Science ®Google Scholar
• Caraglia M, Santini D, Marra M, Vincenzi B, Tonini G, Budillon A. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 2006;13:7–26.
   PubMed Web of Science ®Google Scholar
• Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13:581–9.
   PubMed Web of Science ®Google Scholar
• Nogawa M, Yuasa T, Kimura S, Kuroda J, Segawa H, Sato K, . Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells. Oncol Res 2005;15:1–9.
   PubMed Web of Science ®Google Scholar
• Ullen A, Lennartsson L, Harmenberg U, Hjelm-Eriksson M, Kalkner KM, Lennernas B, . Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol 2005;44:644–50.
   PubMed Web of Science ®Google Scholar
• Fabbri F, Brigliadori G, Carloni S, Ulivi P, Vannini I, Tesei A, . Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. J Transl Med 2008;6:43.
   PubMed Web of Science ®Google Scholar
• Adany I, Yazlovitskaya EM, Haug JS, Voziyan PA, Melnykovych G. Differences in sensitivity to farnesol toxicity between neoplastically- and non-neoplastically-derived cells in culture. Cancer Lett 1994;79:175–9.
   PubMed Web of Science ®Google Scholar
• Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997;57:229–33.
   PubMed Web of Science ®Google Scholar
• Miquel K, Pradines A, Favre G. Farnesol and geranylgeraniol induce actin cytoskeleton disorganization and apoptosis in A549 lung adenocarcinoma cells. Biochem Biophys Res Commun 1996;225:869–76.
   PubMed Web of Science ®Google Scholar
• Rioja A, Pizzey AR, Marson CM, Thomas NS. Preferential induction of apoptosis of leukaemic cells by farnesol. FEBS Lett 2000;467:291–5.
   PubMed Web of Science ®Google Scholar
• Maestre N, Bezombes C, Plo I, Levade T, Lavelle F, Laurent G, . Phosphatidylcholine-derived phosphatidic acid and diacylglycerol are involved in the signaling pathways activated by docetaxel. J Exp Ther Oncol 2003;3:36–46.
   PubMedGoogle Scholar
• Joo JH, Liao G, Collins JB, Grissom SF, Jetten AM. Farnesol-induced apoptosis in human lung carcinoma cells is coupled to the endoplasmic reticulum stress response. Cancer Res 2007;67:7929–36.
   PubMed Web of Science ®Google Scholar
• Joo JH, Jetten AM. Molecular mechanisms involved in farnesol-induced apoptosis. Cancer Lett 2010;287:123–135.
   PubMed Web of Science ®Google Scholar